Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Immunovant (NASDAQ:IMVT) issued its earnings results on Wednesday. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.13), FiscalAI reports. During the same period in the prior year, the business posted ($0.64) earnings per share.

Here are the key takeaways from Immunovant’s conference call:

• Roivant reported strong preliminary open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, with roughly 73% ACR20, more than half achieving ACR50, and over a third reaching ACR70. Management emphasized that responses were seen in a heavily refractory population, including many patients who had failed both JAK inhibitors and TNFs.
• The company said IMVT-1402 was safe and well tolerated in the study, with no new drug-related safety signals identified. Management also said across hundreds of patients dosed to date, they have seen no impact on albumin or LDL.
• Roivant noted that the RA study’s period 2 randomized withdrawal portion is still ongoing, and management plans to use additional patient-level analysis plus FDA feedback to determine the path forward. They suggested the strong period 1 data could support a potentially lean registrational strategy.
• The company highlighted encouraging progress for mosociguat in PH-ILD, including phase I data showing deep pulmonary vascular resistance reductions and good tolerability without meaningful systemic side effects. In the phase II FOCUS study, Roivant said enrollment is complete and 95%+ of patients reached the 4 mg dose, with top-line data expected in the second half of 2026.
• Roivant reiterated a strong broader pipeline outlook, including expected repotrectinib launch in dermatomyositis by the end of September, ongoing development in cutaneous sarcoidosis and nail lichen planus, and continued enrollment in Graves’ disease and other FcRn programs. The company also ended the quarter with $4.3 billion in cash and equivalents before the Moderna settlement payment.

Immunovant Price Performance

NASDAQ:IMVT opened at $35.56 on Thursday. Immunovant has a 12-month low of $13.79 and a 12-month high of $36.29. The firm has a market capitalization of $7.24 billion, a P/E ratio of -13.22 and a beta of 0.70. The business has a 50 day simple moving average of $26.48 and a 200 day simple moving average of $25.78.

Insider Buying and Selling at Immunovant

In related news, Director Atul Pande sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $32.00, for a total transaction of $192,000.00. Following the completion of the transaction, the director owned 116,731 shares in the company, valued at $3,735,392. The trade was a 4.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Tiago Girao sold 25,760 shares of the business’s stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $29.62, for a total value of $763,011.20. Following the transaction, the chief financial officer owned 247,596 shares of the company’s stock, valued at $7,333,793.52. This represents a 9.42% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 78,141 shares of company stock worth $2,115,713. 1.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMVT. Strs Ohio acquired a new position in Immunovant during the 1st quarter worth $27,000. PNC Financial Services Group Inc. boosted its position in Immunovant by 138.9% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,831 shares of the company’s stock worth $46,000 after acquiring an additional 1,646 shares during the period. Quarry LP boosted its position in Immunovant by 94.9% during the 4th quarter. Quarry LP now owns 3,000 shares of the company’s stock worth $76,000 after acquiring an additional 1,461 shares during the period. Tower Research Capital LLC TRC boosted its position in Immunovant by 228.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,140 shares of the company’s stock worth $98,000 after acquiring an additional 4,273 shares during the period. Finally, Royal Bank of Canada boosted its position in Immunovant by 20.7% during the 4th quarter. Royal Bank of Canada now owns 4,549 shares of the company’s stock worth $116,000 after acquiring an additional 780 shares during the period. Institutional investors and hedge funds own 47.08% of the company’s stock.

Analyst Ratings Changes

IMVT has been the subject of several research reports. HC Wainwright lifted their target price on Immunovant from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday. Sanford C. Bernstein initiated coverage on Immunovant in a research report on Friday, March 20th. They issued a “market perform” rating and a $28.00 target price for the company. The Goldman Sachs Group lifted their target price on Immunovant from $29.00 to $32.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunovant in a research report on Wednesday, April 8th. Finally, Guggenheim lifted their target price on Immunovant from $41.00 to $44.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Six research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $33.00.

Trending Headlines about Immunovant

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Immunovant reported strong Week 16 results from its rheumatoid arthritis study of IMVT-1402, with encouraging response rates that investors viewed as clinically meaningful and supportive of the drug’s potential. Article Title
• Positive Sentiment: The company said its cutaneous lupus proof-of-concept trial is fully enrolled and expects topline data in the second half of 2026, giving investors another near-term catalyst. Article Title
• Positive Sentiment: Immunovant also highlighted a cash position of about $902 million as of March 31, which should help fund development and support the path toward a possible commercial launch of IMVT-1402 in Graves’ disease. Article Title
• Neutral Sentiment: Quarterly results were weaker than expected, with a loss of $0.73 per share versus the $0.60 estimate, but the earnings miss was largely overshadowed by the clinical update. Article Title
• Negative Sentiment: Director Atul Pande sold 6,000 shares in a pre-arranged transaction, which may slightly temper sentiment even though it was disclosed under a Rule 10b5-1 plan. Article Title

About Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.